Collegium Pharmaceutical Inc. (COLL)
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.42 per share. This compares to earnings of $1.49 per share a year ago.
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript
Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference
Collegium Pharmaceutical (NASDAQ: COLL) highlighted a "record-breaking" 2025 and outlined its 2026 outlook at the Barclays Miami Conference, emphasizing strong performance from newly acquired ADHD product JORNAY PM alongside what management described as a durable pain portfolio. Management recaps a record 2025 CEO Vikram Karnani said 2025 delivered record net revenues and record adjusted EBITDA, alongside
Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical: Buying The Projected Growth For 2026
Collegium Pharmaceutical demonstrates strong profitability, upgraded 2026 guidance, and a robust balance sheet, reinforcing my bullish outlook and conviction upgrade. COLL's growth is shifting from Xtampza ER to Jornay PM, which is expected to drive $190M–$200M in 2025 revenue and deeper ADHD market penetration. The pain portfolio remains a stable cash generator, with authorized generics providing a smart revenue stream and mitigating immediate generic erosion risks.
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stocks to Buy for Dec. 18
KE, COLL and JRVR made it to the Zacks Rank #1 (Strong Buy) value stocks list on Dec. 18, 2025.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
